Pharmesis International Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, revenue was RMB 17,275,000 against RMB 16,012,000 a year ago. Loss from operations was RMB 74,000 against income of RMB 817,000 a year ago. Loss before tax was RMB 255,000 against profit of RMB 593,000 a year ago. Loss attributable to the owners of the company was RMB 454,000 against profit of RMB 150,000 a year ago. Net cash from operating activities was RMB 1,747,000 against net cash used in operating activities of RMB 3,121,000 a year ago. Acquisition of property, plant and equipment was RMB 120,000 against RMB 1,398,000 a year ago. On fully diluted basis loss per share was 2.0 cents against earnings of 0.8 cents a year ago. The group's revenue increased 7.9%, mainly due to higher revenue from the group's non-prescribed drugs/distribution segment, offset by lower revenue from prescribed drugs segment. The group's net cash inflow from operating activities for the second quarter was mainly due to cash generated from its operations and changes in working capital. For the six months, revenue was RMB 31,588,000 against RMB 30,050,000 a year ago. Loss before tax was RMB 1,314,000 against profit of RMB 744,000 a year ago. Loss from operations was RMB 982,000 against income of RMB 80,000 a year ago. Loss attributable to the owners of the company was RMB 1,550,000 against profit of RMB 446,000 a year ago. Net cash used in operating activities was RMB 117,000 against RMB 1,652,000 a year ago. Acquisition of property, plant and equipment was RMB 329,000 against RMB 1,402,000 a year ago. On fully diluted basis loss per share was 6.7 cents against earnings of 2.2 cents a year ago.